HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmitz, J. Articles by Schaper, F. Search for Related Content PubMed PubMed Citation Articles by Schmitz, J. Articles by Schaper, F.

The Cytoplasmic Tyrosine Motifs in Full-Length Glycoprotein 130 Have Different Roles in IL-6 Signal Transduction¹

Institut für Biochemie Rheinisch-Westfälische Technische Hochschule \E (RWTH), Aachen, Germany

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
The function of the signal-transducing receptor subunit glycoprotein 130 (gp130) in the IL-6-receptor complex has previously been studied using carboxyl-terminal deletion mutants or a truncated molecule of 60 membrane-proximal amino acids (containing box 1 and box 2) linked to the individual gp130 tyrosine motifs. However, the redundancy of the tyrosine motifs within the cytoplasmic part of gp130 has been neglected. Here we describe the analysis of the function of the individual cytoplasmic tyrosine residues of gp130 in the context of the full-length receptor protein in IL-6 signaling as measured by STAT activation, acute phase protein induction, and stimulation of proliferation. Add-back receptor mutants containing only one cytoplasmic tyrosine have been generated and tested for their efficiency in IL-6 signal transduction. Our studies revealed that tyrosine motifs which have been described to recruit STAT proteins are not equivalent with respect to their potential to activate STAT factors and acute phase protein gene promoters: the two distal tyrosines, Tyr⁹⁰⁵ and Tyr⁹¹⁵, of gp130 were more potent than Tyr⁷⁶⁷ and Tyr⁸¹⁴. Surprisingly, Tyr⁹⁰⁵ and Tyr⁹¹⁵ mediate acute phase protein gene promoter activation stronger than the wild-type receptor containing all six cytoplasmic tyrosine residues. In contrast, Ba/F3 cells stably transfected with add-back receptors containing Tyr⁷⁶⁷ or Tyr⁹⁰⁵ were more sensitive to IL-6-induced proliferation than cells expressing the other add-back receptor mutants. Thus, the tyrosine residues in the cytoplasmic part of gp130 were found to contribute differentially to IL-6 signal transduction in the full- length gp130 protein.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Interleukin-6 was first described as a B cell-stimulating factor (1) which induces the differentiation and proliferation of B and T cells. Furthermore, IL-6 is the major mediator of acute phase protein (APP)³ expression in rat hepatocytes in vitro (2, 3) and in rats in vivo (4). IL-6 signals through the glycoprotein 130 (gp130)/Janus kinase (Jak)/STAT pathway (5, 6). Upon ligand binding to the -receptor subunit gp80, the signal-transducing receptor subunit gp130 dimerizes, and activation of constitutively gp130-associated tyrosine kinases of the Jak family Jak1, Jak2, and Tyk2 occurs. Subsequently, the receptor is tyrosine phosphorylated, and STAT factors (5, 6) and the Src homology domain 2 protein tyrosine phosphatase (SHP2) (7) are recruited via their Src homology 2 domains (8, 9), resulting in STAT and SHP2 phosphorylation on tyrosine residues. The tyrosine-phosphorylated STAT factors homo- or heterodimerize (10) and translocate to the nucleus, where they bind to enhancer elements of respective IL-6 target genes (11). In contrast, SHP2 acts negatively on acute phase protein induction (12, 13, 14) and is involved in the activation of the mitogen-activated protein kinase (MAPK) pathway by IL-6 (15).

Previous work of Stahl et al. (7) and Gerhartz et al. (16) has shown that the four distal tyrosine modules of gp130 are involved in STAT activation. Both groups have used in their experiments the individual tyrosine modules linked to the box 1 and 2 region of gp130. It was found that the last four tyrosine modules stimulate STAT3 phosphorylation, whereas STAT1 was activated by the two distal tyrosine modules. The consensus sequences YXPQ and YXXQ were proposed for STAT1 (16) and STAT3 (7, 16) activation, respectively. Furthermore, Tyr⁷⁵⁹ was identified to be crucial for the phosphorylation of the tyrosine phosphatase SHP2 (7).

However, the contributions of the individual tyrosines within the context of the whole cytoplasmic tail of gp130 in IL-6 signaling have not been studied yet. The purpose of this work was to determine whether the entire cytoplasmic part of gp130 affects the potential of the different tyrosine residues to activate IL-6 signal transduction. In the present paper, we show that the tyrosine residues 767, 814, 905, and 915 are not equivalent with respect to the induction of STAT3 tyrosine phosphorylation, DNA binding, reporter gene activation, and stimulation of proliferation when investigated in the context of the full-length gp130 receptor protein. Furthermore, our data are contrary to the observation previously published by Fukada et al. (15) who showed, using a cytoplasmically truncated G-CSF/gp130 chimeric receptor, that a single STAT recruitment site in gp130 (Tyr⁷⁶⁷) is not sufficient for IL-6-mediated proliferation in gp130-transfected Ba/F3 cells. From our results, it must be concluded that the full-length cytoplasmic part of gp130 modulates the functionality of the individual tyrosine motifs in IL-6 signal transduction.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials

Restriction enzymes were purchased from Boehringer Mannheim (Mannheim, Germany) and AGS (Heidelberg, Germany), oligonucleotides were synthesized by MWG-Biotech (Ebersberg, Germany). Vent polymerase and Abs to the Tyr⁷⁰⁵-phosphorylated STAT3 were obtained from New England BioLabs (Beverly, MA). Abs to gp130 were gifts from Dr. J. Wijdenes (Besançon, France). Recombinant erythropoietin (Epo) was a generous gift of Drs. J. Burg and K. H. Sellinger (Boehringer Mannheim). Recombinant IL-6 and sIL-6R were prepared as described earlier (17, 18). The specific activity of IL-6 was 2 x 10⁶ B cell-stimulatory factor-2 U/mg of protein.

Construction of expression vectors

Constructions were conducted by standard procedures (19). pGL32 M-215Luc contains the promoter region -215 to +8 of the rat ₂-macroglobulin (2M) gene fused to the luciferase-encoding sequence and was described previously (12). pGL3-hACT-359LUC was cloned by inserting the promoter region (-379 to +25) of the human ₁-antichymotrypsin into pGL3 (Promega, Madison, WI) and kindly provided by F. Horn (Leipzig, Germany).

The expression vector pSVL-EG encoding the chimeric Epo/gp130 receptor (16) was modified by PCR mutagenesis to introduce recognition sites for restriction enzymes between the cytoplasmic tyrosines (pSVL-EG(YYYYYY) (tyrosine residues in the wild-type cytoplasmic part of gp130 are boldfaced). These mutations were designed not to change the encoding amino acid sequence. The introduced restriction sites were the following: SacI between Tyr⁶⁸³ and Tyr⁷⁵⁹; BspEI between Tyr⁷⁵⁹ and Tyr⁷⁶⁷; AspI between Tyr⁷⁶⁷ and Tyr⁸¹⁴; Bsp119I between Tyr⁸¹⁴ and Tyr⁹⁰⁵; and RsrII between Tyr⁹⁰⁵ and Tyr⁹¹⁵. pSVL-EG(FFFFFF) was constructed similarly to pSVL-EG(YYYYYY) and contains additional YF substitutions in the six cytoplasmic tyrosine motifs.

These two vectors were used to construct add-back mutants by combining appropriate DNA fragments of the cytoplasmic part of gp130, resulting in pSVL-EG(YFFFFF), pSVL-EG(FYFFFF), pSVL-EG(FFYFFF), pSVL-EG(FFFYFF), pSVL-EG(FFFFYF), and pSVL-EG(FFFFFY). Also add-back mutants containing two tyrosines were prepared: pSVL-EG(YYFFFF); pSVL-EG(FYYFFF); pSVL-EG(FYFYFF); pSVL-EG(FYFFYF); and pSVL-EG(FYFFFY).

The DNA fragments encoding the Epo/gp130 chimeric receptors mutants were also transferred into pRc/CMV-EG (16) and used for expression in HepG2 cells (e.g., pRc/CMV-EG(YFFFFF)).

The DNA fragment coding for the transmembrane and cytoplasmic domains of the chimeric receptor mutants was also introduced into pSVL-gp130 (20) (e.g., pSVL-gp130 (YFFFFF)). The latter constructs were used for the generation of stably transfected Ba/F3 cells.

The sequences of all constructs have been verified by fluorescence sequencing.

Transfection and reporter gene analysis

Human hepatoma HepG2 cells were cultivated and transient transfections by the calcium phosphate coprecipitation method were performed as described previously (21). Cell lysis and luciferase assays were conducted with the Promega luciferase kit according to the manufacturer’s instructions. Three independent transfections have been performed. Luciferase activity values were normalized to transfection efficiency monitored by the cotransfected -galactosidase expression vector (pCR3lacZ, Pharmacia, Uppsala, Sweden). The error bars are SD.

Ba/F3 cells were cultivated and stably transfected as described previously (20). Equal expression levels of gp130 protein were verified by FACS analysis with the B-P4 Ab specific for the extracellular domain of gp130 (20, 22). For each receptor mutant, two independent stable transfections were performed and found to give similar results in the experiments executed (data not shown).

Nuclear extract preparation and electrophoretic mobility shift assay (EMSA)

Nuclear extracts of Ba/F3 cells were prepared, protein concentration was measured by the Bio-Rad protein assay, and EMSA was performed as previously described (20). We used a STAT1- and STAT3-specific double-stranded ³²P-labeled probe: a mutated serum-inducible element (SIE) oligonucleotide of the c-fos promoter (m67 SIE: 5'-GATCCGGGAGGGATTTACGGGAAATGCTG-3'). Protein-DNA complexes were separated on 4.5% polyacrylamide gels containing 7.5% glycerol in 0.25x Tris-borated EDTA buffer at 20 V/cm for 4 h. Gels were fixed in 10% methanol, 10% acetic acid, and 80% water for 30 min; dried; and autoradiographed.

Immunoblot analysis

Equal amounts of nuclear extracts were separated by SDS-PAGE (7% gel) and transferred to a polyvinylidene fluoride membrane. Ags were detected by incubation with the appropriate primary Ab (1:1000) and HRP-coupled secondary Abs (1:1000) (Dako, Hamburg, Germany). The membranes were developed with an enhanced chemiluminescence kit (Amersham-Buchler, Braunschweig, Germany). To verify application of equal amounts of protein, blots were stripped and reprobed.

Cell proliferation assay

Ba/F3 cells (2 x 10⁴) expressing gp130 receptor mutants were cultured in DMEM containing the indicated concentrations of IL-6 and 1 µg/ml soluble (s) IL-6R or conditioned medium from X63Ag-653 BPV-mIL-3 myeloma cells as a source of IL-3. After 72 h of incubation, viable and metabolically active cells were quantified by using the colorimetric Cell Proliferation Kit II (XTT) (Boehringer Mannheim) as described by the manufacturer. Values represent the average of three independent experiments ± SD.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Construction and expression of gp130 receptor mutants

A crucial step in the activation of SHP2 and STAT factors in IL-6 signal transduction is their recruitment to phosphotyrosine residues of the signal transducer gp130. To examine the role of the individual tyrosine motifs in the context of the full-length gp130, a cloning strategy has been established that allowed us to generate all the possible gp130 mutants with YF substitutions in its cytoplasmic part. Therefore, two gp130 DNA constructs have been generated, containing either all six cytoplasmic tyrosine codons or a substitution of all tyrosine to phenylalanine codons. Additionally, these two constructs contain new unique restriction sites, which do not alter the amino acid sequence of the receptors, between all tyrosine or phenylalanine positions. These restriction sites enabled us to exchange single or combinations of tyrosine motifs of gp130 between both receptor mutants (for details, see Materials and Methods).

The gp130 mutants used in this work contain either all, none, or only a single tyrosine (add back mutants) of the six cytoplasmic tyrosine residues present in the wild-type human gp130 receptor protein (Fig. 1A). All constructs were stably transfected into IL-3-dependent Ba/F3 cells, which do not express endogenous gp130 (23). Receptor surface expression of the transfected Ba/F3 cells was monitored by FACS analysis with the use of an Ab raised against the extracellular domain of gp130 (22) and found to be comparable for all transfectants (Fig. 1B).

View larger version (41K): [in this window] [in a new window]   FIGURE 1. Schematic representation of the various gp130 mutants and their surface expression. A, gp130 receptor mutants were generated as described in Materials and Methods. A scheme of the positions of the resulting tyrosine (Y)phenylalanine (F) substitutions introduced into the wild-type gp130 cytoplasmic domain is shown. B, Surface expression of the various gp130 mutants in stably transfected Ba/F3 cells monitored by FACS analysis with Abs specific to the extracellular domain of gp130. FL2-H, fluorescence intensity.

To compare the capabilities of the single tyrosine motifs with respect to STAT activation, the stably transfected Ba/F3 cells, expressing the add-back mutants of gp130 (Fig. 1), were stimulated with IL-6/sIL-6R complexes. Nuclear extracts from these cells were analyzed for DNA-binding activities in an EMSA with DNA probes providing binding sites for STAT3 and STAT1 (Fig. 2). No DNA-binding activity was found in nuclear extracts from untransfected Ba/F3 cells. Stimulation of cells expressing the wild-type gp130 receptor protein (gp130(YYYYYY)) led to the formation of protein-DNA complexes containing STAT3 homodimers and to a lower extent STAT1 homodimers and STAT1/STAT3 heterodimers. No protein-DNA complex formation was detected after stimulation of Ba/F3 cells transfected with the receptor mutant gp130(FFFFFF).

View larger version (59K): [in this window] [in a new window]   FIGURE 2. Induction of STAT3-DNA binding through single STAT recruitment sites in full-length gp130. Stably transfected Ba/F3 cells, expressing the indicated gp130 mutants, were stimulated with 20 ng/ml IL-6 and 1 µg/ml sIL-6R for 15 min. Nuclear extracts were used for EMSAs with a STAT3/STAT1-specific DNA probe (m67SIE) as described in Materials and Methods. Left, STAT3 and STAT1 homo- and heterodimers bound to the labeled DNA probe.

Kinetics of STAT3-DNA binding and phosphorylation

A time course experiment was elaborated to investigate the kinetics of STAT3 activation via the individual tyrosines in the context of the whole gp130 protein. Ba/F3 cells stably expressing the gp130 receptor mutants described in Fig. 1 were stimulated with IL-6/sIL-6R complexes up to 60 min and analyzed for STAT3-DNA binding in EMSAs (Fig. 3A). Stimulation of Ba/F3 cells expressing the wild-type gp130 receptor resulted in maximal STAT3-DNA binding between 20 and 30 min after stimulation. The add-back receptor mutants (gp130(FFYFFF), gp130(FFFYFF), gp130(FFFFYF), and gp130(FFFFFY)) which were found to mediate STAT3-DNA binding showed a weaker stimulation than gp130(YYYYYY) but similar kinetics.

View larger version (45K): [in this window] [in a new window]   FIGURE 3. Kinetics of STAT3 activation. A, Cells were stimulated for the times indicated, and EMSAs were performed as described in the legend to Fig. 2. Arrowheads, STAT3 homodimer/DNA complexes. B, Cellular extracts from the stably transfectd Ba/F3 cells described in the legend to Fig. 2 were separated by SDS-PAGE. The proteins were blotted and immunodetected with a STAT3-P-Tyr705-specific Ab (upper panels) and reprobed with a STAT3-specific Ab (lower panels). Arrowheads, STAT3.

Gene induction via single tyrosines of the activated gp130 receptor

STAT3 is the most important transcription factor for the induction of the APP genes (24). It exerts its action by binding to the enhancer sequences of APP gene promoters (11). In reporter assays the capability of single tyrosines in the cytoplasmic part of gp130 to mediate activation of APP gene promoters in the human hepatoma cell line HepG2 was analyzed. Chimeric receptors containing the extracellular domain of the EpoR and the transmembrane and the cytoplasmic domains of the various gp130 mutants (Fig. 1A) allowed us to induce IL-6 signal transduction in HepG2 cells independent from endogenous gp130. Vectors encoding these chimeric receptor mutants were cotransfected with a construct harboring the promoter of the 2M gene linked to the luciferase reporter gene (pGL32M-215Luc) (Fig. 4A).

View larger version (15K): [in this window] [in a new window]   FIGURE 4. Acute phase protein gene promoter induction by activated gp130 mutants. HepG2 cells were transiently transfected with constructs coding for chimeric receptor mutants containing the extracellular domain of the murine EpoR and the transmembrane and intracellular domains of gp130 YF mutants described in Fig. 1A. All cells were cotransfected with an 2M promoter-luciferase gene reporter construct (A) or an 1-antichymotrypsin promoter-luciferase gene reporter construct (B) and a -galactosidase-encoding control vector. Three independent transfections were performed for each combination of vectors. Cells were untreated or stimulated with 7 U Epo/ml for 16 h. Luciferase activity was determined and normalized to -galactosidase activity to correct for transfection efficiency. Luciferase expression of the stimulated cells was related to corresponding unstimulated cells. Error bars are SD.

In addition, similar reporter gene assays were performed using the promoter of the APP gene ₁-antichymotrypsin linked to the reporter gene luciferase (Fig. 4B). The results were very similar to those obtained with the 2M promoter reporter gene construct (Fig. 4A). We conclude from these data that the add-back mutants containing one of the four distal tyrosines differ in their potency to activate APP gene promoters.

Influence of Tyr⁷⁵⁹ on reporter gene induction by individual membrane-distal tyrosines of gp130

To elucidate the influence of the SHP2 recruitment site in gp130 on STAT-mediated gene induction, chimeric receptor add-back mutants containing Tyr⁷⁵⁹ plus one of the four membrane-distal cytoplasmic tyrosine residues (Fig. 5A) were also analyzed in the reporter gene assay with the 2M gene promoter/luciferase construct (Fig. 5B). Epo stimulation of HepG2 cells expressing the chimeric receptors EG(FYFFYF) or EG(FYFFFY) led essentially to the same luciferase induction compared with the wild-type receptor (EG(YYYYYY)) indicating an influence of Tyr⁷⁵⁹ on the gene induction through the distal tyrosine motifs (compare EG(FFFFYF) in Fig. 4A with EG(FYFFYF) in Fig. 5B or EG(FFFFFY) in Fig. 4A with EG(FYFFFY) in Fig. 5B). Activation of receptors containing no STAT-binding sites did not result in significant reporter gene induction. Interestingly, the 2M promoter-luciferase reporter activation in cells expressing the receptors EG(FYYFFF) or EG(FYFYFF) was strongly reduced when compared with the EG(YYYYYY) receptor demonstrating the importance of the most distal tyrosine motifs in gp130.

View larger version (27K): [in this window] [in a new window]   FIGURE 5. Influence of Tyr759 on the induction of the 2M promoter/reporter gene by individual tyrosines of gp130. A, Schematic representation of various gp130 mutants containing the extracellular domain of the murine EpoR, and the transmembrane and intracellular domains of gp130 YF mutants with Tyr759 and a second cytoplasmic tyrosine at permutated positions. B, HepG2 cells were transiently transfected with constructs coding for the chimeric receptor mutants. Transfection and determination of 2M promoter-luciferase gene reporter expression was performed as described in the legend to Fig. 4.

Proliferation of transfected Ba/F3 cells expressing gp130 can be induced by stimulation with IL-6/sIL-6R (23). Up to now there are only scarce data regarding the role of individual tyrosines in the full-length gp130 for IL-6-induced proliferation. Therefore, we investigated the proliferation of the Ba/F3 transfectants expressing the gp130 add-back mutants (Fig. 1). The cells were stimulated with increasing amounts of IL-6/sIL-6R complexes for 72 h. Subsequently, the viable and metabolically active cells were quantified (Fig. 6A). No proliferation of untransfected cells was observed. Cells expressing a gp130 mutant lacking all cytoplasmic tyrosine residues (gp130(FFFFFF)) and cells expressing the gp130 mutants gp130(YFFFFF) or gp130(FYFFFF) did not proliferate even at the highest concentration of IL-6/sIL-6R. In contrast, a dose-dependent proliferative response was observed for gp130(YYYYYY) transfectants (Fig. 6A, top). The stably transfected Ba/F3 cells expressing the gp130 add-back mutants containing only one of the four distal tyrosines, which were found to mediate STAT3 activation (Fig. 2), show also an IL-6 dose-dependent growth stimulation. In several independent experiments, we found that the receptors gp130(FFFYFF) and gp130(FFFFFY) are weaker signal transducers with respect to the IL-6/sIL-6R-induced proliferation (Fig. 6A, bottom) than the wild-type gp130 receptor protein (Fig. 6A, top) indicating that the level of STAT3 activation did not correspond to the proliferative activity. For control, cells of the different Ba/F3 cell lines were incubated with a conditioned medium of IL-3-expressing cells (Fig. 6B). No differences were found for the stably transfected Ba/F3 cells with regard to their IL-3-dependent proliferative response.

View larger version (19K): [in this window] [in a new window]   FIGURE 6. Cell proliferation induced through single tyrosines in gp130. Stably transfected Ba/F3 cells (as described in Fig. 1B) were analyzed in a proliferation assay. After 72 h of stimulation with increasing amounts of IL-6 at a constant concentration of soluble human IL-6R (1 µg/ml) (A) or IL-3-containing conditioned medium (B), the proliferation of the cells was measured using the colorimetric XTT assay. Values represent the average of three independent experiments; error bars are SD. BPV, conditioned medium from X63Ag-653 BPV-mIL-3 myeloma cells as a source of IL-3.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

In addition to these data on the modular organization of gp130, information about the tertiary structure of the cytoplasmic tail is not available. Undoubtedly, the three-dimensional structure of the cytoplasmic part of the gp130 molecule may also influence the activation of the signaling components such as Jaks, SHP2, and STATs. Generation of add-back mutants allowed us to examine the potential of the six individual cytoplasmic tyrosine motifs in the context of the full-length receptor (Fig. 1). Indeed, we found that these receptor mutants are not equivalent with regard to STAT activation, acute phase protein induction, and stimulation of cell proliferation. We confirmed that STAT1 and STAT3 are activated only via the four most distal tyrosine motifs (Tyr⁷⁶⁷, Tyr⁸¹⁴, Tyr⁹⁰⁵, and Tyr⁹¹⁵) (Fig. 2). Interestingly however, add-back receptor mutants with only one of the two most distal tyrosines (Tyr⁹⁰⁵ or Tyr⁹¹⁵) were more potent to mediate STAT activation than the receptors containing the proximal tyrosines. These differences were not simply due to altered kinetics of STAT activation (Fig. 3). Therefore, we propose that the individual tyrosine motifs of gp130 are not equivalent in their capacity to activate STAT factors in the context of the full-length cytoplasmic part of gp130.

Thus far, these differences in the potential of the individual STAT recruitment sites of gp130 have not yet been taken into consideration. To examine, whether they affect biological activities of IL-6, such as acute phase protein expression in liver cells, we analyzed the potential of the add-back mutants to activate promoters of the two APP genes 2M and ₁-antichymotrypsin. As expected, we found that only receptor mutants that activate STAT factors are able to mediate APP gene induction. Similar to the pattern of STAT activation, the add-back receptors containing Tyr⁹⁰⁵ or Tyr⁹¹⁵ were the most efficient ones to activate APP gene promoters. Surprisingly, these two add-back mutants, containing only a single cytoplasmic tyrosine, were much more potent than the wild-type receptor subunit containing all six tyrosine motifs. This implies an inhibitory function on APP gene induction through one of the four membrane-proximal cytoplasmic tyrosine residues. We were able to localize the inhibitory tyrosine at position 759: the addition of Tyr⁷⁵⁹ in the add-back mutants reduced the efficiency of the individual receptors to mediate 2M promoter activation. None of these add-back mutants containing Tyr⁷⁵⁹ plus one of the other five tyrosines was more potent in 2M promoter activation than the receptor containing all six tyrosine motifs. This is consistent with the observation that SHP2, which binds to Tyr⁷⁵⁹, negatively regulates STAT activation and APP gene induction (12, 13, 14). Thus, SHP2 does not affect individual tyrosine motifs in gp130 but acts in a more general manner. Recently, it has been published that activation of the MAPK pathway results in a reduction of STAT phosphorylation (27), which is in line with the fact that SHP2 phosphorylation after IL-6 stimulation leads to the induction of the MAPK pathway (15).

In addition to STAT and APP promoter activation, we examined the potency of all gp130 add-back mutants with respect to the proliferation of Ba/F3 cells. Ba/F3 cells proliferate in response to IL-3 or after transfection of gp130 in response to IL-6/sIL-6R (23). We found that all receptors that mediate STAT activation also stimulate proliferation. However, the strength of STAT and APP gene promoter induction via the individual add-back receptor mutants did not correlate with their ability to stimulate proliferation. Ba/F3 cells expressing receptor mutants containing only a single STAT recruitment site are less sensitive to IL-6 (Fig. 6A, bottom) than cells expressing the wild-type receptor (Fig. 6A, top). This finding implies that STAT activation is not the only prerequisite for maximal IL-6-induced Ba/F3 cell proliferation. The lower efficiency of the receptor mutants in mediating proliferation might reflect the presence of only one STAT recruitment site or the lack of a protein activated by the wild-type receptor but not by these mutants. None of the two proximal tyrosine motifs is essential for proliferation, because receptor mutants with a YF substitutions at amino acid positions Tyr⁶⁸³ and Tyr⁷⁵⁹ still mediate IL-6-induced Ba/F3 cell proliferation. Nevertheless, we cannot exclude an influence of these tyrosines on the IL-6-induced proliferation of gp130-transfected Ba/F3 cells.

Our observation that a gp130 add-back mutant containing a single STAT-binding tyrosine is sufficient for IL-6 induced proliferation is in contrast to the data of Fukada et al. (15). Their studies have been performed with chimeric receptors composed of the extracellular domain of the G-CSF-R, the transmembrane domain of gp130, and a truncated cytoplasmic part of gp130 lacking the three distal tyrosine motifs. Thus, their receptor contains only one STAT recruitment site (Tyr⁷⁶⁷), the SHP2 recruitment site (Tyr⁷⁵⁹) and Tyr⁶⁸³. The requirement of both STAT3 and SHP2 for Ba/F3 cell proliferation was derived from the results with YF substitutions within the truncated part of gp130. Only receptors containing the STAT as well as the SHP2-recruiting tyrosine were able to mediate cell proliferation. In summary, the authors found STAT3 to inhibit apoptosis and SHP2 to exert a mitogenic signal. The requirement of Tyr⁷⁵⁹ in gp130 for proliferation was confirmed in Ba/F3 cells expressing a G-CSF-R/gp130 chimeric receptor mutant, which contains the full-length cytoplasmic part of gp130 but a mutation of the SHP2 recruitment site (15). These cells do not proliferate but survive in response to stimulation with G-CSF.

Fukada et al. (15) supposed that the deleted region, including the three distal STAT-recruitment sites, in their chimeric G-CSF-R/gp130 receptors is negligible for IL-6 signal transduction. In contrast, we performed our experiments with a full-length gp130 receptor with point mutations of the individual cytoplasmic tyrosine residues. Thus, the mutation of the individual tyrosines in gp130 compared with a deletion of the whole C-terminal region led to different biological responses. One can assume that the differences in the cytoplasmic parts of the receptor mutants used in both studies cause the different requirements for SHP2 with regard to stimulation of proliferation.

In conclusion, we suggest that the role of the entire cytoplasmic part of gp130 must be taken into account, and the data obtained with truncated chimeric receptor mutants should be considered with caution and be confirmed by the use of the respective full-length native receptors.

	Acknowledgments

 
We thank Iris Behrmann and Lutz Graeve for critical reading of the manuscript and Sonja Linnemann for excellent technical assistance.

	Footnotes

 
¹ This work was supported by grants from the Deutsche Forschungsgemeinschaft (Bonn, Germany) and the Fonds der Chemischen Industrie (Frankfurt/Main, Germany).

² Address correspondence and reprint requests to Dr. Peter C. Heinrich, Medical School, RWTH Aachen, Department of Biochemistry, Pauwelsstrasse 30, D-52074 Aachen, Germany. E-mail address:

³ Abbreviations used in this paper: APP, acute phase protein; 2M, ₂-macroglobulin; EMSA, electrophoretic mobility shift assay; Epo, erythropoietin; gp130, glycoprotein 130; Jak, Janus kinase; MAPK, mitogen-activated protein kinase; s, soluble; SHP2, Scr homology domain 2-containing phosphatase 2; SIE, serum inducible-element.

Received for publication June 29, 1999. Accepted for publication November 1, 1999.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Hirano, T., T. Taga, N. Nakano, K. Yasukawa, S. Shimitzu, K. Kawashimura, K. Nakajima, K. H. Pjun, T. Kishimoto. 1985. Purification to homogeneity and characterization oh human B cell differentiation factor (BCDF or BSF-2). Proc. Natl. Acad. Sci. USA 82:5490.[Abstract/Free Full Text]
2. Castell, J. V., M. J. Gomez-Lechon, M. David, T. Hirano, T. Kishimoto, P. C. Heinrich. 1988. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 232:347.[Medline]
3. Castell, J. V., M. J. Gomez-Lechon, M. David, R. Fabra, R. Trullenque, P. C. Heinrich. 1990. Acute phase response of human hepatocytes: regulation of acute phase protein synthesis by interleukin-6. Hepatology 12:1179.[Medline]
4. Geiger, T., T. Andus, J. Klapproth, T. Hirano, T. Kishimoto, P. C. Heinrich. 1988. Induction of rat acute phase proteins by interleukin 6 in vivo. Eur. J. Immunol. 18:717.[Medline]
5. Lütticken, C., U. M. Wegenka, J. Yuan, J. Buschmann, C. Schindler, A. Ziemiecki, A. G. Harpur, A. F. Wilks, K. Yasukawa, T. Taga, T. Kishimoto, G. Barbieri, S. Pellegrini, M. Sendtner, P. C. Heinrich, F. Horn. 1994. Association of transcription factor APRF and protein kinase Jak 1 with the interleukin-6 signal transducer gp130. Science 263:89.[Abstract/Free Full Text]
6. Stahl, N., T. G. Boulton, T. Farruggella, N. Y. Ip, S. Davis, B. A. Witthuhn, F. W. Quelle, O. Silvennoinen, G. Barbieri, S. Pellegrini, J. N. Ihle, G. D. Yancopoulos. 1994. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 b receptor components. Science 263:92.[Abstract/Free Full Text]
7. Stahl, N., T. J. Farruggella, T. G. Boulton, Z. Zhong, Jr J. E. Darnell, G. D. Yancopoulos. 1995. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267:1349.[Abstract/Free Full Text]
8. Hemmann, U., C. Gerhartz, B. Heesel, J. Sasse, G. Kurapkat, J. Grötzinger, A. Wollmer, Z. Zhong, Jr J. E. Darnell, L. Graeve, P. C. Heinrich, F. Horn. 1996. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. 2. Src homology SH2 domains define the specificity of STAT factor activation. J. Biol. Chem. 271:12999.[Abstract/Free Full Text]
9. Heim, M. H., I. M. Kerr, G. R. Stark, Jr J. E. Darnell. 1995. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 267:1347.[Abstract/Free Full Text]
10. Zhong, Z., Z. Wen, Jr J. E. Darnell. 1994. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95.[Abstract/Free Full Text]
11. Wegenka, U. M., J. Buschmann, C. Lütticken, P. C. Heinrich, F. Horn. 1993. Acute phase response factor, a nuclear factor binding to acute phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol. Cell. Biol. 13:276.[Abstract/Free Full Text]
12. Schaper, F., C. Gendo, M. Eck, J. Schmitz, C. Grimm, D. Anhuf, I. M. Kerr, P. C. Heinrich. 1998. Activation of SHP2 via the IL-6 signal transducing receptor protein gp130 requires JAK1 and limits acute phase protein expression. Biochem. J. 335:557.
13. Symes, A., N. Stahl, S. A. Reeves, T. Farruggella, T. Servidei, T. Gearan, G. Yancopoulos, J. S. Fink. 1997. The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neurotrophic factor induction of gene expression. Curr. Biol. 7:697.[Medline]
14. Kim, H. K., T. S. Hawley, R. G. Hawley, H. Baumann. 1998. Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute phase plasma protein genes in hepatic cells. Mol. Cell. Biol. 18:1525.[Abstract/Free Full Text]
15. Fukada, T., M. Hibi, Y. Yamanaka, M. Takahashitezuka, Y. Fujitani, T. Yamaguchi, K. Nakajima, T. Hirano. 1996. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 5:449.[Medline]
16. Gerhartz, C., B. Heesel, J. Sasse, U. Hemmann, C. Landgraf, J. Schneider-Mergener, F. Horn, P. C. Heinrich, L. Graeve. 1996. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. 1. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J. Biol. Chem. 271:12991.[Abstract/Free Full Text]
17. Arcone, R., P. Pucci, F. Zappacosta, V. Fontaine, A. Marloni, G. Marino, G. Ciliberto. 1991. Single-step purification and structural characterization of human interleukin-6 produced in Escherichia coli form a T7 RNA polymerase expression vector. Eur. J. Biochem. 198:541.[Medline]
18. Weiergräber, O., U. Hemmann, A. Erren, G. Müller-Newen, J. Schneider, S. Rose-John, P. Kurschat, J. P. J. Brakenhoff, M. H. L. Hart, S. Stabel, P. C. Heinrich. 1995. Soluble human interleukin-6 receptor: expression in insect cells, purification and characterization. Eur. J. Biochem. 234:661.[Medline]
19. Sambrook, J., E. F. Frisch, T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
20. Horsten, U., G. Müller-Newen, C. Gerhartz, A. Wollmer, J. Wijdenes, P. C. Heinrich, J. Grötzinger. 1997. Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6)·IL-6 receptor · gp130 complex. J. Biol. Chem. 272:23748.[Abstract/Free Full Text]
21. Yuan, J., U. M. Wegenka, C. Lütticken, J. Buschmann, T. Decker, C. Schindler, P. C. Heinrich, F. Horn. 1994. The signalling pathways of interleukin-6 and gamma interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol. Cell. Biol. 14:1657.[Abstract/Free Full Text]
22. Wijdenes, J., P. C. Heinrich, G. Müller-Newen, C. Roche, Z. J. Gu, C. Clement, B. Klein. 1995. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur. J. Biochem. 25:3474.
23. Murakami, M., M. Narazaki, M. Hibi, H. Yawata, K. Yasukawa, M. Hamaguchi, T. Taga, T. Kishimoto. 1991. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc. Natl. Acad. Sci. USA 88:11349.[Abstract/Free Full Text]
24. Heinrich, P. C., I. Behrmann, L. Graeve, J. Grötzinger, S. Haan, F. Horn, U. Horsten, I. M. Kerr, P. May, G. Müller-Newen, F. Schaper, L. Terstegen, S. Thiel. 1998. The acute phase response of the liver: molecular mechanism of IL-6 signalling from the plasma membrane to the nucleus. ed. Signalling in the Liver 55. Kluwer Academic Publishers, Dordrecht.
25. Narazaki, M., B. A. Witthuhn, K. Yoshida, O. Silvennoinen, K. Yasukawa, J. N. Ihle, T. Kishimoto, T. Taga. 1994. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc. Natl. Acad. Sci. USA 91:2285.[Abstract/Free Full Text]
26. Haan, S., U. Hemmann, U. Hassiepen, F. Schaper, J. Schneider-Mergener, A. Wollmer, P. C. Heinrich, J. Grötzinger. 1999. Characterization and binding specificity of the monomeric STAT3-SH2 domain. J. Biol. Chem. 15:1342.
27. Sengupta, T. K., E. S. Talbot, P. A. Scherle, L. B. Ivashkiv. 1998. Rapid inhibition of interleukin-6 signaling and stat3 activation mediated by mitogen-activated protein kinases. Proc. Natl. Acad. Sci. USA 95:11107.[Abstract/Free Full Text]

This article has been cited by other articles:

				G. D. Kalliolias and L. B. Ivashkiv IL-27 Activates Human Monocytes via STAT1 and Suppresses IL-10 Production but the Inflammatory Functions of IL-27 Are Abrogated by TLRs and p38 J. Immunol., May 1, 2008; 180(9): 6325 - 6333. [Abstract] [Full Text] [PDF]

				C. Ehlting, W. S. Lai, F. Schaper, E. D. Brenndorfer, R.-J. Matthes, P. C. Heinrich, S. Ludwig, P. J. Blackshear, M. Gaestel, D. Haussinger, et al. Regulation of Suppressor of Cytokine Signaling 3 (SOCS3) mRNA Stability by TNF-{alpha} Involves Activation of the MKK6/p38MAPK/MK2 Cascade J. Immunol., March 1, 2007; 178(5): 2813 - 2826. [Abstract] [Full Text] [PDF]

				F. Hu and J. Nicholas Signal Transduction by Human Herpesvirus 8 Viral Interleukin-6 (vIL-6) Is Modulated by the Nonsignaling gp80 Subunit of the IL-6 Receptor Complex and Is Distinct from Signaling Induced by Human IL-6 J. Virol., November 1, 2006; 80(21): 10874 - 10878. [Abstract] [Full Text] [PDF]

				U. Sommer, C. Schmid, R. M. Sobota, U. Lehmann, N. J. Stevenson, J. A. Johnston, F. Schaper, P. C. Heinrich, and S. Haan Mechanisms of SOCS3 Phosphorylation upon Interleukin-6 Stimulation: CONTRIBUTIONS OF Src- AND RECEPTOR-TYROSINE KINASES J. Biol. Chem., September 9, 2005; 280(36): 31478 - 31488. [Abstract] [Full Text] [PDF]

				B. Chen, S. Tsui, and T. J. Smith IL-1{beta} Induces IL-6 Expression in Human Orbital Fibroblasts: Identification of an Anatomic-Site Specific Phenotypic Attribute Relevant to Thyroid-Associated Ophthalmopathy J. Immunol., July 15, 2005; 175(2): 1310 - 1319. [Abstract] [Full Text] [PDF]

				X.-P. Yang, U. Albrecht, V. Zakowski, R. M. Sobota, D. Haussinger, P. C. Heinrich, S. Ludwig, J. G. Bode, and F. Schaper Dual Function of Interleukin-1{beta} for the Regulation of Interleukin-6-induced Suppressor of Cytokine Signaling 3 Expression J. Biol. Chem., October 22, 2004; 279(43): 45279 - 45289. [Abstract] [Full Text] [PDF]

				L. Zhao, S. Hart, J. Cheng, J. J. Melenhorst, B. Bierie, M. Ernst, C. Stewart, F. Schaper, P. C. Heinrich, A. Ullrich, et al. Mammary Gland Remodeling Depends on gp130 Signaling through Stat3 and MAPK J. Biol. Chem., October 15, 2004; 279(42): 44093 - 44100. [Abstract] [Full Text] [PDF]

				B. Giese, C.-K. Au-Yeung, A. Herrmann, S. Diefenbach, C. Haan, A. Kuster, S. B. Wortmann, C. Roderburg, P. C. Heinrich, I. Behrmann, et al. Long Term Association of the Cytokine Receptor gp130 and the Janus Kinase Jak1 Revealed by FRAP Analysis J. Biol. Chem., October 3, 2003; 278(40): 39205 - 39213. [Abstract] [Full Text] [PDF]

				C. Niemand, A. Nimmesgern, S. Haan, P. Fischer, F. Schaper, R. Rossaint, P. C. Heinrich, and G. Muller-Newen Activation of STAT3 by IL-6 and IL-10 in Primary Human Macrophages Is Differentially Modulated by Suppressor of Cytokine Signaling 3 J. Immunol., March 15, 2003; 170(6): 3263 - 3272. [Abstract] [Full Text] [PDF]

				D. E. Isaksen, H. Baumann, B. Zhou, S. Nivollet, A. G. Farr, S. D. Levin, and S. F. Ziegler Uncoupling of Proliferation and Stat5 Activation in Thymic Stromal Lymphopoietin-Mediated Signal Transduction J. Immunol., April 1, 2002; 168(7): 3288 - 3294. [Abstract] [Full Text] [PDF]

				M. Schaeffer, M. Schneiderbauer, S. Weidler, R. Tavares, M. Warmuth, G. de Vos, and M. Hallek Signaling through a Novel Domain of gp130 Mediates Cell Proliferation and Activation of Hck and Erk Kinases Mol. Cell. Biol., December 1, 2001; 21(23): 8068 - 8081. [Abstract] [Full Text] [PDF]

				S. Pflanz, I. Kurth, J. Grotzinger, P. C. Heinrich, and G. Muller-Newen Two Different Epitopes of the Signal Transducer gp130 Sequentially Cooperate on IL-6-Induced Receptor Activation J. Immunol., December 15, 2000; 165(12): 7042 - 7049. [Abstract] [Full Text] [PDF]

				D. Anhuf, M. Weissenbach, J. Schmitz, R. Sobota, H. M. Hermanns, S. Radtke, S. Linnemann, I. Behrmann, P. C. Heinrich, and F. Schaper Signal Transduction of IL-6, Leukemia-Inhibitory Factor, and Oncostatin M: Structural Receptor Requirements for Signal Attenuation J. Immunol., September 1, 2000; 165(5): 2535 - 2543. [Abstract] [Full Text] [PDF]

				H. M. Hermanns, S. Radtke, F. Schaper, P. C. Heinrich, and I. Behrmann Non-redundant Signal Transduction of Interleukin-6-type Cytokines. THE ADAPTER PROTEIN Shc IS SPECIFICALLY RECRUITED TO THE ONCOSTATIN M RECEPTOR J. Biol. Chem., December 22, 2000; 275(52): 40742 - 40748. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmitz, J. Articles by Schaper, F. Search for Related Content PubMed PubMed Citation Articles by Schmitz, J. Articles by Schaper, F.